Recent announcements by Pfizer and BioNTech SE, Moderna, and AstraZeneca on their coronavirus vaccines have been promising. With so many companies racing to develop a vaccine, there are certain to be additional announcements forthcoming, ideally with comparable or even better efficacy data, less stringent cold-chain storage requirements, and even less adverse side effects. Although there are many more hurdles to traverse, establishing the efficacy of a vaccine in less than one year is nothing short of remarkable.
St. Louis Post-Dispatch/December 7, 2020